贵阳朗玛信息技术股份有限公司董事会 关于独立董事独立性评估的专项意见 经核查，公司在任独立董事陈文德先生、杨小舟先生的任职经历以及签署的 相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司 主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可 能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况。 因此，公司在任独立董事陈文德先生、杨小舟先生符合《上市公司独立董事 管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》中关于独立董事的任职资格及独立性的要求。 贵阳朗玛信息技术股份有限公司（以下简称"公司"）董事会根据《上市公 司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等要求，就公司在 任独立董事陈文德先生、杨小舟先生的独立性情况进行评估并出具如下专项意见： 贵阳朗玛信息技术股份有限公司董事会 2025 年 4 月 23 日 ...

（一）工作履历、专业背景及兼职情况 本人陈文德，1963 年出生，中国国籍，无境外永久居留权，硕士学历。2023 年 12 月 29 日至今任江苏亚虹医药科技股份有限公司董事，2023 年 3 月至今任 公司独立董事。 贵阳朗玛信息技术股份有限公司 2024 年度独立董事述职报告 （陈文德） 作为贵阳朗玛信息技术股份有限公司（以下简称"公司"）第五届董事会的 独立董事，2024 年度，本人严格按照《公司法》《证券法》《上市公司独立董 事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等相关法律法规、规范性文件及《公司章程》《独立董事工作制度》 等有关规定，认真行使公司赋予的权利，及时了解公司的经营信息，全面关注公 司的发展状况，积极出席公司召开的相关会议，对公司董事会审议的相关事项发 表了独立客观的意见，忠实履行职责，监督公司规范化运作，充分发挥独立董事 的独立作用，维护了全体股东尤其是中小股东的合法权益。现将 2024 年度本人 履行独立董事职责的工作情况报告如下： 一、基本情况 （二）独立性说明 在担任公司独立董事期间，本人未在公司担任除独立董事、董事会专门委员 会委 ...

Financial Performance - The company reported a significant impairment loss of CNY 566.48 million related to goodwill from the acquisition of Qisheng Information, leading to a substantial decline in net profit for the reporting period[4]. - The company's operating revenue for 2024 was ¥379,069,416.43, a decrease of 17.52% compared to ¥459,582,706.22 in 2023[19]. - The net profit attributable to shareholders for 2024 was -¥512,099,676.96, representing a decline of 761.14% from ¥77,457,117.42 in 2023[19]. - The net cash flow from operating activities decreased by 44.93% to ¥47,950,182.50 in 2024 from ¥87,075,703.27 in 2023[19]. - The total assets at the end of 2024 were ¥1,326,100,361.07, down 29.55% from ¥1,882,211,378.44 at the end of 2023[19]. - The company achieved a total revenue of 37,906.94 million yuan in 2024, representing a decline of 17.52% compared to the previous year[38]. - The net profit attributable to shareholders was -51,209.97 million yuan, a decrease of 761.14% year-on-year, primarily due to a goodwill impairment provision of 56,648.16 million yuan[38]. - The company reported a basic earnings per share of -¥1.52 for 2024, a decrease of 760.87% from ¥0.23 in 2023[19]. - The weighted average return on net assets was -38.04% in 2024, down 42.97% from 4.93% in 2023[19]. Revenue Sources - The company's medical services and internet healthcare services generated revenue of ¥27,879.91 million in 2024, accounting for 73.55% of total operating revenue[29]. - The revenue from the medical services segment increased by 8.93% to ¥216,235,395.90, while the mobile resale business saw a significant decline of 40.26% to ¥82,857,488.56[70]. - Revenue for the pharmaceutical e-commerce segment was CNY 2,367.20 million, a decrease of 4.77% year-over-year, while net profit increased by 9.99% to CNY 86.90 million[53]. - Revenue from the mobile communication resale business was CNY 83.70 million, down 39.67% year-over-year, with net profit decreasing by 37.94% to CNY 26.01 million[55]. Business Strategy and Development - The company plans to increase investment in research and development, particularly in the field of medical artificial intelligence, to foster new growth points for performance[5]. - The company is actively expanding into new industries while continuing to deepen its main business[6]. - The company is leveraging its vast medical data resources and technological advantages to enhance its position in the medical artificial intelligence sector[5]. - The company aims to deepen the integration of AI and medical services, positioning itself as a leader in the healthcare technology sector[62]. - The company is focusing on the integration of AI technology in medical services, aiming to innovate service models and enhance resource allocation[62]. - The company aims to leverage its extensive medical data resources and technological advantages to enhance service efficiency and reduce healthcare costs[114]. Challenges and Risks - The mobile resale business faced revenue declines due to stricter regulatory policies, impacting user growth and overall income[4]. - The company acknowledges the potential risks in future development plans and emphasizes the importance of investor awareness regarding these risks[6]. - The company is facing challenges such as intensified market competition, exploration of profitability in internet healthcare, and regulatory changes[115]. Research and Development - The company is focusing on enhancing AI capabilities in medical health information to improve content flow and expand customer base[50]. - The company is developing an AI-based chronic disease management system to provide personalized health management services, enhancing patient quality of life and reducing healthcare costs[83]. - The company is developing an AI-based voice enhancement algorithm to improve audio and video quality, which is expected to enhance product competitiveness[80]. - A distributed architecture-based online consultation system is under development to better serve the internet medical platform[81]. - The company has completed the development of an intelligent video generation system driven by AI technology, aimed at automating the production and editing of educational videos[84]. Governance and Management - The company held its first extraordinary general meeting of shareholders in 2024 on March 6, with a participation rate of 37.89%[127]. - The annual general meeting of shareholders for 2023 was held on May 16, 2024, with a participation rate of 35.41%[127]. - The company has seen significant leadership changes, with multiple executives leaving and new appointments made in 2024[133]. - The company is focusing on expanding its leadership team with experienced professionals to enhance operational efficiency and strategic direction[135]. - The company has established a remuneration and assessment committee to propose remuneration standards[146]. Employee and Compensation - The total number of employees at the end of the reporting period was 810, with 116 in technical roles and 498 in medical roles[158][159]. - The company has implemented a competitive compensation policy, including basic salary, performance bonuses, and various allowances, aimed at enhancing employee satisfaction and retention[160]. - The total pre-tax remuneration for the board of directors, supervisors, and senior management during the reporting period amounted to CNY 4.4678 million[147]. Market Position and Recognition - The company was ranked 64th in the "Top 100 Internet Enterprises Comprehensive Strength Index" in 2024, being the only internet healthcare company on the list[32]. - The user base for internet healthcare in China has reached 418 million, with telemedicine services covering all cities and counties[114]. Future Outlook - In 2025, the company plans to expand its AI healthcare business, including strengthening market development in collaboration with government departments and building internet healthcare platforms[116]. - The company aims to solidify its position in the pharmaceutical distribution business by establishing a modern pharmaceutical logistics benchmark in the province through scaled operations and specialized logistics[116].

Financial Performance - The company's operating revenue for Q1 2025 was ¥72,986,749.97, a decrease of 8.15% compared to ¥79,459,636.01 in the same period last year[6]. - Net profit attributable to shareholders increased by 2.77% to ¥6,495,378.69 from ¥6,320,115.93 year-on-year[6]. - Basic and diluted earnings per share rose by 2.67% to ¥0.0192 from ¥0.0187 year-on-year[6]. - Net profit for the current period is ¥5,863,127.17, an increase of 7.3% compared to ¥5,465,039.19 in the previous period[27]. Cash Flow - The net cash flow from operating activities surged by 1,773.96% to ¥22,056,783.01, compared to ¥1,177,013.52 in the previous year[6]. - The net cash flow from operating activities increased significantly to ¥22,056,783.01 from ¥1,177,013.52, marking a substantial improvement[30]. - The company's cash and cash equivalents increased to ¥308,947,348.08 from ¥283,539,885.31, representing a growth of approximately 9.5%[22]. - Cash and cash equivalents at the end of the period increased to ¥308,297,144.98 from ¥286,895,774.33, reflecting a growth of 7.4%[30]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,339,840,762.03, reflecting a 1.04% increase from ¥1,326,100,361.07 at the end of the previous year[6]. - Total current assets reached ¥405,783,322.55, up from ¥386,251,415.91, reflecting a growth of approximately 5.1%[23]. - Non-current assets decreased slightly to ¥934,057,439.48 from ¥939,848,945.16, a decline of about 0.6%[23]. - Total liabilities increased to ¥237,991,477.55 from ¥230,114,203.76, which is an increase of about 3.8%[24]. - The company's equity remained stable with total equity at ¥1,101,849,284.48, consistent with previous periods[24]. - The company reported a total equity attributable to shareholders of ¥1,086,346,959.52, up from ¥1,079,851,580.83[25]. - The total liabilities and equity amounted to ¥1,339,840,762.03, an increase from ¥1,326,100,361.07[25]. Expenses - The company's research and development expenses decreased by 32.55% compared to the same period last year, primarily due to reduced labor costs in R&D projects[14]. - Research and development expenses decreased to ¥7,488,633.37 from ¥11,102,265.54, a reduction of 32.5%[26]. - The company's sales expenses increased by 55.56% year-on-year, mainly due to agency fees paid by Guangzhou Qisheng Information Technology Co., Ltd. and promotional expenses incurred by Liuyi Company[14]. - Total operating costs decreased to ¥71,029,427.61 from ¥77,159,993.40, reflecting a reduction of 7.9%[26]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 43,568[17]. - The largest shareholder, Wang Wei, holds 31.99% of the shares, totaling 108,115,315 shares[17]. Investment Activities - The company's investment activities generated a net cash flow increase of 332.43%, primarily due to cash received from investment income[15]. - The company recorded an investment income of ¥4,585,684.72, down from ¥5,202,682.54, a decline of 11.8%[26]. Other Financial Metrics - The subsidiary Qisheng Information has been re-certified as a high-tech enterprise, allowing it to enjoy a reduced corporate income tax rate of 15% for three consecutive years from 2024 to 2026[20]. - The company reported a decrease in other receivables to ¥25,295,813.47 from ¥34,829,612.97, a decline of approximately 27.5%[23]. - The company’s contract liabilities decreased to ¥16,556,289.29 from ¥18,540,527.97, indicating a reduction of about 10.7%[24].

Group 1 - The core viewpoint of the news is that Langma Information's stock has experienced a decline, with a closing price of 13.02 yuan and a rolling PE ratio of 77.05 times, which is higher than the industry average [1] - The total market capitalization of Langma Information is 4.4 billion yuan, ranking 106th in the internet services industry based on PE ratio [1][2] - The company has seen a net outflow of main funds amounting to 20.69 million yuan on April 24, with a total outflow of 22.89 million yuan over the past five days [1] Group 2 - Langma Information's main business segments include "medical services + internet medical services" and "telecommunications and value-added telecommunications services" [1] - The latest financial results for the third quarter of 2024 show that the company achieved an operating income of 298 million yuan, a year-on-year decrease of 14.20%, and a net profit of 40.98 million yuan, a year-on-year decrease of 33.18% [1] - The gross profit margin for the company stands at 36.56% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Langma Information, with a current stock price of 13.39 yuan and a PE ratio of 79.24 times, indicating a higher valuation compared to the industry average [1][2] - Langma Information's total market capitalization is reported at 4.525 billion yuan, ranking 107th in the internet services sector, which has an average PE ratio of 66.95 times and a median of 68.26 times [1][2] - The company has experienced a net inflow of main funds amounting to 2.0256 million yuan on April 14, with a total inflow of 5.0269 million yuan over the past five days, indicating positive investor sentiment [1] Group 2 - Langma Information operates in two main business segments: "medical services + internet medical services" and "telecommunications and value-added telecommunications services," with key products including telephone services, mobile resale, and medical information services [1] - The latest financial results for the third quarter of 2024 show a revenue of 298 million yuan, representing a year-on-year decrease of 14.20%, and a net profit of 40.9792 million yuan, down 33.18% year-on-year, with a gross profit margin of 36.56% [1]

| 贵阳朗玛投 资咨询企业 | 首次公开发 行前持股、资 | 集中竟价 | 2025年3月31日 | 13. 87 | 168. 97 | 0. 50% | | --- | --- | --- | --- | --- | --- | --- | | (有限合伙) | 本公积金转 | 交易 | -2025年4月8日 | | | | | | 增股 | | | | | | | | | 合计 | | | 337. 94 | 1.00% | 控股股东、实际控制人王伟及其一致行动人朗玛投资咨询合计减持337.94万股，减持比例为1%。经中 国经济网记者计算，依照减持均价，控股股东、实际控制人王伟及其一致行动人朗玛投资咨询合计减持 金额约为4906.89万元。 中国经济网北京4月10日讯朗玛信息（300288）(300288.SZ)昨晚发布关于控股股东、实际控制人及其一 致行动人减持完成的公告。 朗玛信息于2025年1月18日在指定信息披露媒体巨潮资讯网披露了《关于公司控股股东、实际控制人及 其一致行动人减持股份的预披露公告》(公告编号：2025-001)，公司控股股东、实际控制人王伟及其一 致行动人贵阳朗玛投资咨询企业( ...

贵阳朗玛信息技术股份有限公司 关于控股股东、实际控制人及其一致行动人减持完成的公告 证券代码：300288 证券简称：朗玛信息 公告编号：2025-005 | 贵阳朗玛投 | 首次公开发 行前持股、资 | 集中竞价 | 2025年3月31日 | | | | | --- | --- | --- | --- | --- | --- | --- | | 资咨询企业 | | | | 13.87 | 168.97 | 0.50% | | （有限合伙） | 本公积金转 | 交易 | -2025年4月8日 | | | | | | 增股 | | | | | | | | | 合计 | | | 337.94 | 1.00% | 公司控股股东、实际控制人王伟先生及其一致行动人贵阳朗玛投资咨询企业 （有限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 贵阳朗玛信息技术股份有限公司（以下简称"公司"）于2025年1月18日在 指定信息披露媒体巨潮资讯网披露了《关于公司控股股东、实际控制人及其一致 行动人减持股份的预披露公告》（ ...

Company Overview - Langma Information closed at 12.84 yuan, up 3.97%, with a rolling PE ratio of 75.98 times and a total market value of 4.339 billion yuan [1] - The company operates in two main business segments: "Medical Services + Internet Medical Services" and "Telecommunications and Value-Added Telecommunications Services" [1] - Key products include telephone services, mobile resale services, medical information services, and software sales [1] Financial Performance - For the third quarter of 2024, the company reported revenue of 298 million yuan, a year-on-year decrease of 14.20% [1] - Net profit for the same period was 40.98 million yuan, down 33.18% year-on-year, with a gross profit margin of 36.56% [1] Shareholder Information - As of March 31, 2025, the number of shareholders was 43,568, a decrease of 1,940 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Industry Comparison - The average PE ratio for the internet services industry is 62.03 times, with a median of 64.27 times, placing Langma Information at rank 109 [2] - The industry median PE ratio is 64.27 times, while the average is 62.03 times [2]

整数倍的公告 证券代码：300288 证券简称：朗玛信息 公告编号：2025-004 公司控股股东、实际控制人王伟先生及其一致行动人贵阳朗玛投资咨询企业 （有限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 贵阳朗玛信息技术股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 贵阳朗玛信息技术股份有限公司（以下简称"公司"）于2025年1月18日在 指定信息披露媒体巨潮资讯网披露了《关于公司控股股东、实际控制人及其一致 行动人减持股份的预披露公告》（公告编号：2025-001），公司控股股东、实际 控制人王伟先生及其一致行动人贵阳朗玛投资咨询企业（有限合伙）（以下简称 "朗玛投资咨询"）计划自上述公告披露之日起15个交易日后的3个月内（即2025 年2月18日至2025年5月17日）通过集中竞价交易方式减持公司股份合计不超过 3,379,500股，即不超过公司总股本337,941,402股的1%。 公司于近日收到控股股东、实际控制人王伟先生及其一致行动人朗玛投资咨 询出具的《关于减持股份比例触及1%整数倍的告知函》，自2025年3月31日至 ...